169 related articles for article (PubMed ID: 30196301)
1. Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.
Thadhani R; Guilatco R; Hymes J; Maddux FW; Ahuja A
Am J Nephrol; 2018; 48(3):214-224. PubMed ID: 30196301
[TBL] [Abstract][Full Text] [Related]
2. Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
Fishbane S; Singh B; Kumbhat S; Wisemandle WA; Martin NE
Clin J Am Soc Nephrol; 2018 Aug; 13(8):1204-1214. PubMed ID: 29921734
[TBL] [Abstract][Full Text] [Related]
3. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.
Azmandian J; Abbasi MR; Pourfarziani V; Nasiri AA; Ossareh S; Ezzatzadegan Jahromi S; Sanadgol H; Amini S; Shahvaroughi Farahani A
Am J Nephrol; 2018; 48(4):251-259. PubMed ID: 30253403
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
6. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
Haag-Weber M; Vetter A; Thyroff-Friesinger U;
Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
[TBL] [Abstract][Full Text] [Related]
9. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
10. Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients.
Minutolo R; Borzumati M; Sposini S; Abaterusso C; Carraro G; Santoboni A; Mura C; Filiberti O; Santoro D; Musacchio R; Imperiali P; Fiorini F; De Nicola L; Russo D
Am J Kidney Dis; 2016 Jul; 68(1):170-2. PubMed ID: 26879099
[No Abstract] [Full Text] [Related]
11. Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study.
Hustrini NM; Siregar P; Setiawati A; Nugroho P
Acta Med Indones; 2019 Jul; 51(3):230-237. PubMed ID: 31699946
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
13. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
14. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.
Hahn D; Esezobor CI; Elserafy N; Webster AC; Hodson EM
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011690. PubMed ID: 28066881
[TBL] [Abstract][Full Text] [Related]
15. Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States.
Anand S; Al-Mondhiry J; Fischer K; Glaspy J
Expert Rev Clin Pharmacol; 2021 Jan; 14(1):1-8. PubMed ID: 33307871
[No Abstract] [Full Text] [Related]
16. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
Biggar P; Ketteler M; Hennemann H; Dömling R
Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
[TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
[TBL] [Abstract][Full Text] [Related]
18. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
Pussell BA; Walker R
Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
[TBL] [Abstract][Full Text] [Related]
19. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
Coyne DW; Singh AK; Lopes RD; Bailey CK; DiMino TL; Huang C; Connaire J; Rastogi A; Kim SG; Orias M; Shah S; Patel V; Cobitz AR; Wanner C
Clin J Am Soc Nephrol; 2022 Sep; 17(9):1325-1336. PubMed ID: 35918106
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]